Point72 Asset Management L.P. Buys Shares of 26,600 Takeda Pharmaceutical Company Limited (NYSE:TAK)

Point72 Asset Management L.P. acquired a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 26,600 shares of the company's stock, valued at approximately $352,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. First Trust Advisors LP increased its position in Takeda Pharmaceutical by 2.0% during the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock worth $42,910,000 after purchasing an additional 62,718 shares in the last quarter. Van ECK Associates Corp increased its position in Takeda Pharmaceutical by 1.6% in the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company's stock valued at $29,266,000 after acquiring an additional 35,192 shares during the period. Northern Trust Corp increased its position in Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after acquiring an additional 238,161 shares during the period. Summit Global Investments increased its position in Takeda Pharmaceutical by 75.5% in the 4th quarter. Summit Global Investments now owns 729,200 shares of the company's stock valued at $9,655,000 after acquiring an additional 313,642 shares during the period. Finally, BNP Paribas Financial Markets increased its position in Takeda Pharmaceutical by 15,449.0% in the 4th quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock valued at $6,629,000 after acquiring an additional 497,457 shares during the period. Institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.8%

Shares of TAK traded up $0.11 during trading hours on Tuesday, reaching $14.68. 2,148,568 shares of the stock traded hands, compared to its average volume of 1,930,038. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $14.68 and a 200 day simple moving average of $14.02. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.43. The company has a market cap of $46.71 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. On average, equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.